When Is FDA Form 3500A Required? (w/Examples) + FAQs

FDA Form 3500A is required whenever a mandatory adverse event report must be submitted to the Food and Drug Administration. The form applies to manufacturers, importers, and user facilities that must report deaths, serious injuries, or malfunctions linked to medical products under federal law.

The governing regulation for medical devices is 21 CFR Part 803, which specifies exact timeframes and requirements for submissions. For drugs and biologics, 21 CFR 314.80 and 600.80 govern postmarketing safety reports. Failure to submit required reports can result in FDA Warning Letters, product seizures, or even license revocation.

According to a recent MAUDE database analysis, approximately 96.5% of all mandatory medical device reports come from manufacturers, while user facilities and importers make up the remainder. This shows that most healthcare facilities are either unaware of their reporting duties or struggle to meet the requirements.

What you will learn in this article:

📋 Exactly when FDA Form 3500A is required and who must file it

⏰ Specific deadlines for different product types (5, 10, 15, or 30 days)

⚠️ Common mistakes that lead to FDA Warning Letters and how to avoid them

📝 Step-by-step guidance on completing each section of the form

❓ Answers to the most frequently asked questions about mandatory reporting

What Is FDA Form 3500A?

FDA Form 3500A is the official document for mandatory adverse event reporting to the Food and Drug Administration. Unlike voluntary Form 3500, which healthcare professionals and consumers use to report problems, Form 3500A carries legal obligations.

The form serves several critical purposes. It creates a permanent record of safety issues with FDA-regulated products. It allows the agency to detect patterns that might indicate a broader public health problem. And it provides data that may lead to recalls, label changes, or even product withdrawal from the market.

Form 3500A applies to multiple product categories under FDA oversight. These include prescription and over-the-counter drugs, biological products like blood components and vaccines, medical devices ranging from tongue depressors to MRI machines, human cells and tissue products (HCT/Ps), cosmetics (since December 2023), and dietary supplements.

The form itself spans several pages with distinct sections. Section A captures patient information. Section B describes the adverse event or product problem. Section C covers suspect drug or biological products. Section D focuses specifically on medical devices. Sections E through H gather information about reporters, user facilities, importers, and manufacturers.

Who Must Use Form 3500A?

Mandatory reporting applies to specific groups based on their relationship to the product and the type of event that occurred.

Medical Device Manufacturers

Device manufacturers have the broadest reporting obligations. They must report whenever they learn that any of their devices may have caused or contributed to a death or serious injury. They must also report when a device has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction were to recur.

Medical Device Importers

Importers who bring foreign-made devices into the United States share similar responsibilities. They must report deaths, serious injuries, and malfunctions to the FDA. They are also required to submit reports electronically through the Electronic Submissions Gateway (ESG).

Device User Facilities

A “device user facility” includes hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, and outpatient treatment facilities. Importantly, physician offices are not considered user facilities under this definition.

User facilities must report device-related deaths to both the FDA and the manufacturer. For serious injuries, they report only to the manufacturer (or to the FDA if the manufacturer is unknown).

Drug and Biologic Manufacturers

Pharmaceutical companies holding approved New Drug Applications (NDAs) or Biologic License Applications (BLAs) must report adverse drug experiences. This includes both domestic and foreign events that are serious and unexpected.

IND Sponsors and Sponsor-Investigators

Those conducting clinical trials under Investigational New Drug (IND) applications must submit safety reports on Form 3500A. This applies when a serious and unexpected suspected adverse reaction occurs during the trial.

Dietary Supplement Responsible Persons

The Dietary Supplement and Nonprescription Drug Consumer Protection Act requires manufacturers, packers, and distributors of dietary supplements to report serious adverse events.

Cosmetic Responsible Persons

Since December 29, 2023, the Modernization of Cosmetics Regulation Act (MoCRA) mandates that cosmetic companies report serious adverse events.

Reporting Timeframes by Product Type

The deadline for submitting Form 3500A depends on who is reporting and what product is involved. Missing these deadlines can trigger enforcement action.

Understanding the “Awareness Date”

The clock starts ticking when the reporter “becomes aware” of the event. For manufacturers, this means when any employee first receives information suggesting a reportable event may have occurred. For user facilities, awareness begins when facility personnel identify that a device may have caused or contributed to a reportable event.

The 5-Day Report Exception

Device manufacturers must submit 5-work-day reports in two specific situations. First, when someone in a management or supervisory role becomes aware that a reportable event requires remedial action to prevent an unreasonable risk of substantial harm to public health. Second, when the FDA makes a written request for 5-day reports for specific types of events.

What Qualifies as a “Serious” Adverse Event?

Not every problem with a medical product triggers a mandatory report. The event must meet specific criteria for “seriousness.”

Definition for Drugs and Biologics

Under 21 CFR 314.80, a serious adverse event is one that results in:

• Death
• A life-threatening experience
• Inpatient hospitalization or prolongation of existing hospitalization
• A persistent or significant disability or incapacity
• A congenital anomaly or birth defect
• Any event requiring medical intervention to prevent one of the outcomes above

Definition for Medical Devices

For devices under 21 CFR 803.3, a serious injury is one that:

• Is life-threatening
• Results in permanent impairment of a body function or permanent damage to a body structure
• Necessitates medical or surgical intervention to preclude such permanent impairment or damage

Definition for Cosmetics

Under MoCRA, serious adverse events for cosmetics include those resulting in death, life-threatening experience, hospitalization, disability, congenital anomaly, infection, or significant disfigurement (including serious and persistent rashes, second- or third-degree burns, significant hair loss, or persistent alteration of appearance).

Form 3500A vs. Form 3500: Key Differences

Many people confuse Form 3500A with Form 3500. While they look similar, they serve very different purposes.

As one industry expert noted on LinkedIn, “The 3500A is not just a report—it’s a process.” Hospital risk management systems often support Form 3500 but may not support the mandatory 3500A form, which requires additional coding, risk management, and corrective action sections.

Electronic Submission Requirements

Paper submissions of Form 3500A are becoming increasingly rare. The FDA has established specific electronic submission requirements for different reporter types.

Medical Device Reporting (eMDR)

Since August 2015, manufacturers and importers must submit device reports electronically through the Electronic Submissions Gateway (ESG). User facilities are the exception—they may still submit paper Form 3500A reports.

Drug and Biologic Reporting (FAERS)

Drug and biologic manufacturers must submit individual case safety reports (ICSRs) electronically to the FDA Adverse Event Reporting System (FAERS). The agency accepts submissions in ICH E2B(R3) format through the Electronic Submissions Gateway or the Safety Reporting Portal.

Dietary Supplements and Cosmetics

Dietary supplement companies may use the FDA Safety Reporting Portal for electronic submission. Cosmetic companies can submit reports via email to [email protected] or through the Safety Reporting Portal once fully implemented.

Three Real-World Scenarios

Understanding when Form 3500A applies becomes clearer through specific examples.

Scenario 1: Hospital IV Pump Malfunction

A hospital nurse notices that an IV pump stopped delivering medication to a patient. The patient’s blood pressure dropped significantly, requiring emergency intervention. The patient survived but needed additional hospitalization.

Scenario 2: Drug Manufacturer Receives Foreign Report

A pharmaceutical company’s European affiliate receives a report of a patient who developed Stevens-Johnson syndrome after taking their medication. The reaction was unexpected based on the drug’s labeling.

Scenario 3: Dietary Supplement Causes Hospitalization

A supplement company receives a call from a consumer who was hospitalized after taking their product. The consumer experienced severe liver damage.

Completing Form 3500A: Section-by-Section Guide

The FDA provides detailed instructions for completing Form 3500A. Each section serves a specific purpose.

Section A: Patient Information

This section identifies the individual who experienced the adverse event. Use initials or an identification code—never include the patient’s full name, medical record number, or Social Security number. The FDA holds patient identity in strict confidence.

Include the patient’s age or date of birth, sex, weight, and race/ethnicity. For infants born with congenital anomalies potentially linked to a product used during pregnancy, report the infant as the patient while linking the mother’s product exposure in Section C or D.

Section B: Adverse Event or Product Problem

Check whether the report involves an adverse event, a product problem, or both. Indicate all applicable outcomes: death, life-threatening, hospitalization, disability, congenital anomaly, intervention required, or other serious event.

Provide the date of the event and the date of the report. In the narrative field (B5), describe what happened in detail using the reporter’s own words. Include the medical status before the event, signs and symptoms, clinical course, treatment given, and outcome.

Section C: Suspect Product(s)

For drugs, biologics, dietary supplements, and cosmetics, provide the product name, strength, and manufacturer. Include the dose, frequency, and route of administration. List the diagnosis for which the product was used and the start/stop dates of therapy.

Answer whether the event stopped when the product was discontinued or dose was reduced, and whether the event reappeared after reintroduction. This “dechallenge/rechallenge” information helps establish causality.

Section D: Suspect Medical Device

This section is only for reports involving medical devices. Provide the brand name, common device name, manufacturer name and location, and all identifying numbers (model, lot, catalog, serial, and Unique Device Identifier).

Indicate who was operating the device at the time of the event. Note whether the device was implanted or explanted, and the relevant dates. Indicate if the device is available for FDA evaluation.

Section E: Initial Reporter

Identify the person who first reported the event to you. This could be a healthcare professional, patient, family member, or other individual. Include their name, address, phone number, and occupation.

Section F: User Facility/Importer (Devices Only)

User facilities and importers complete this section. Include your facility’s Health Care Financing Administration (HCFA) number or FDA-assigned identification number. Indicate when you became aware of the event and whether you sent the report to the FDA, the manufacturer, or both.

Section G: All Manufacturers and Responsible Persons

This section applies to all mandatory reporters. Provide your contact information and manufacturing site details. Indicate where you received the report (study, literature, consumer, healthcare professional, etc.).

List any applicable application numbers (NDA, ANDA, BLA, IND, PMA, 510(k)). Indicate the type of report (15-day, 30-day, follow-up, etc.) and your manufacturer report number.

Section H: Device Manufacturers Only

Device manufacturers provide additional details here. Indicate the type of reportable event (death, serious injury, malfunction). Note whether you evaluated the device and summarize your findings.

List any remedial actions taken (repair, replace, relabel, recall, etc.) and whether the event was related to initial use or reuse of the device.

Vaccines: Use VAERS, Not Form 3500A

An important exception exists for vaccines. Adverse events following vaccination must be reported to the Vaccine Adverse Event Reporting System (VAERS), not through Form 3500A.

VAERS is jointly managed by the FDA and the Centers for Disease Control and Prevention (CDC). Healthcare providers are legally required to report certain events listed on the Reportable Events Table, regardless of whether they believe the vaccine caused the event.

Vaccine manufacturers are required by regulation (21 CFR 600.80) to report all adverse events they receive to VAERS. This separate system allows for coordinated vaccine safety surveillance between the two agencies.

Annual Reporting for User Facilities

Device user facilities have an additional obligation beyond individual event reports. They must submit an annual summary report to the FDA using Form FDA 3419.

This annual report summarizes all reportable adverse events submitted to manufacturers or the FDA during the previous calendar year. The report is due by January 1 for events filed in the preceding year (January 1 through December 31).

If a user facility submitted no reportable events during the year, an annual report is not required. The form requires the facility to list the total number of reports, the range of report numbers used, and summary information about each reported event.

Recordkeeping Requirements

Beyond submitting reports, mandatory reporters must maintain records for specified periods.

Records must include raw data, correspondence related to adverse events, and any evaluations performed. The FDA may inspect these records during facility inspections.

Mistakes to Avoid

Failing to comply with mandatory reporting requirements can lead to serious consequences. These are the most common errors.

Mistake 1: Not Recognizing a Reportable Event

Many facilities fail to report because they do not recognize that an event meets the regulatory definition. An event does not need to be proven to be caused by the product—if there is reasonable suggestion that the product may have caused or contributed to the event, it is reportable.

Consequence: The FDA has identified over 2,000 medical device establishments with deficiencies in adverse event reporting. Companies cited for violations reported three times more events in the year before an inspection than in the previous year, suggesting significant underreporting.

Mistake 2: Missing Deadlines

Each reporter type has specific deadlines. Device user facilities have 10 work days. Drug manufacturers have 15 calendar days for expedited reports. Cosmetic companies have 15 business days.

Consequence: In April 2025, the FDA issued a Warning Letter to M.O.M. Enterprises for failing to submit serious adverse event reports within the required 15 business days. The company had received reports of infants choking and stopping breathing but did not file as required.

Mistake 3: Using the Wrong Form

Healthcare professionals sometimes submit Form 3500 (voluntary) when Form 3500A (mandatory) is required. Hospital risk management systems may only support the voluntary form, creating compliance gaps.

Consequence: Reports submitted on the wrong form may not be processed correctly. They may lack required coding and corrective action fields that the FDA expects from mandatory reporters.

Mistake 4: Incomplete Narrative Descriptions

The narrative section (B5) requires sufficient detail for the FDA to understand what happened. Vague or incomplete descriptions delay safety evaluations.

Consequence: The FDA may request follow-up information, extending the investigation timeline. Repeated incomplete submissions may trigger an inspection.

Mistake 5: Failing to Report Follow-Up Information

When new medical information becomes available about a previously reported event, mandatory reporters must submit follow-up reports. For dietary supplements and cosmetics, this applies to information received within one year of the initial report.

Consequence: Failure to report new information within required timeframes can result in enforcement action.

Dos and Don’ts of Form 3500A Reporting

Dos

✅ Do establish written procedures for surveillance, receipt, evaluation, and reporting of adverse events. FDA regulations require that BLA holders and other mandatory reporters develop these procedures.

✅ Do train staff to recognize reportable events. Include training on regulatory definitions of “serious injury,” “malfunction,” and “unexpected.”

✅ Do track the awareness date precisely. This date starts the reporting clock, so document when personnel first learned of the event.

✅ Do report promptly even if investigation is incomplete. Submit initial reports within deadlines and follow up when additional information becomes available.

✅ Do maintain MDR event files with all documentation related to each reported event, including complaint records, investigation notes, and correspondence.

Don’ts

❌ Don’t wait for certainty about causation. Reports are required when there is reasonable possibility of association, not proof.

❌ Don’t dismiss events as “expected.” While expectedness affects drug/biologic reporting requirements, device reporting obligations are not reduced because an event type is known to occur.

❌ Don’t include personal identifiers in narrative sections. Use patient initials only; protect confidentiality.

❌ Don’t assume someone else will report. User facilities must report even if the manufacturer likely knows about the event.

❌ Don’t use Form 3500A for vaccines. Use VAERS instead, even though the form instructions may seem similar.

State-Level Reporting Requirements

While FDA Form 3500A addresses federal requirements, individual states may impose additional reporting obligations.

California, for example, requires hospitals to report adverse events to the California Department of Public Health within specific timeframes. Urgent or emergent events threatening patient welfare must be reported within 24 hours. Most other adverse events must be reported within five calendar days.

These state requirements are separate from and in addition to federal FDA reporting. A hospital that experiences a device-related death must:

1. Report to the device manufacturer within 10 work days (FDA requirement)
2. Report to the FDA within 10 work days (FDA requirement for deaths)
3. Report to the state health department within 24 hours to 5 days (state requirement)
4. Submit annual summary to FDA on Form 3419 (FDA requirement)

Hospitals should maintain procedures that address both federal and state obligations to avoid compliance gaps.

Consequences of Non-Compliance

The FDA takes adverse event reporting violations seriously. Enforcement actions can escalate from observations to Warning Letters to more severe measures.

Form FDA 483 Observations

During inspections, FDA investigators document deficiencies on Form FDA 483. Common observations related to adverse event reporting include:

• Failure to submit reports within required timeframes
• Inadequate procedures for evaluating complaints for reportability
• Incomplete event files or missing documentation
• Failure to maintain records for required retention periods

Warning Letters

If deficiencies are not corrected, the FDA may issue a Warning Letter. Warning Letters are public documents that identify violations and demand corrective action.

Recent Warning Letters have cited companies for failing to report device malfunctions within 30 calendar days, failing to submit dietary supplement serious adverse event reports within 15 business days, and systemic failures in complaint handling systems.

More Severe Actions

Continued non-compliance can lead to:

• Product seizure: The FDA can seize products that are adulterated or misbranded due to reporting failures
• Injunctions: Courts can prohibit companies from manufacturing or distributing products
• License revocation: For biologics, the FDA may revoke a company’s BLA if reporting requirements are not met
• Civil money penalties: Financial penalties may be assessed for certain violations
• Criminal prosecution: Willful violations can result in criminal charges

Additionally, Warning Letters may be used as evidence in product liability lawsuits, creating exposure beyond regulatory enforcement.

Pros and Cons of Mandatory Adverse Event Reporting

Pros

✅ Protects public health by enabling early detection of safety signals that might not appear in clinical trials.

✅ Creates transparency through public databases like FAERS and MAUDE that researchers and patients can access.

✅ Supports regulatory decisions by providing data for recalls, label changes, and safety communications.

✅ Documents company diligence by creating a record of proactive safety monitoring and response.

✅ Standardizes information collection through uniform forms and coding systems that facilitate analysis across products.

Cons

❌ Imposes significant compliance costs including staff training, documentation systems, and electronic submission infrastructure.

❌ Creates potential legal exposure since reports may be discovered in litigation, though device user facility reports have statutory protection.

❌ Requires judgment calls about reportability that may differ between companies and the FDA.

❌ May overwhelm safety systems with high-volume products generating thousands of reports that must be individually evaluated.

❌ Does not prove causation—a common misunderstanding that can lead to misinterpretation of public database information.

FAQs

Is Form 3500A required for every adverse event?
No. Form 3500A is only required for serious adverse events as defined by regulation. Non-serious events may be reported voluntarily but are not mandatory.

Can I submit Form 3500A by fax or mail?
Yes, but with limitations. Device manufacturers and importers must submit electronically. User facilities may still use paper. Other reporters should check current FDA requirements.

Does submitting Form 3500A mean I admit the product caused the event?
No. Federal law explicitly states that submission of a report does not constitute an admission that the product caused or contributed to the event.

Are physician offices required to report on Form 3500A?
No. Physician offices are not user facilities under 21 CFR Part 803. Physicians may report voluntarily using Form 3500.

What happens if I miss the reporting deadline?
You should still submit the report. Late reporting is better than no reporting. Document the delay and implement corrective actions to prevent recurrence.

Do I need to report events that occurred outside the United States?
Yes, for drug and biologic manufacturers. 21 CFR 314.80 requires reporting of serious and unexpected events whether foreign or domestic.

Can consumers submit Form 3500A?
No. Consumers and patients should use Form 3500B for voluntary reporting. Form 3500A is for mandatory reporters only.

Is there a fee to submit Form 3500A?
No. There is no fee for submitting adverse event reports to the FDA.

What if I receive a report about a product that isn’t mine?
Forward it. If you receive a report about another company’s product, forward it to that company. The responsible company must then evaluate and report as required.

Do I need legal counsel to submit Form 3500A?
No, but consulting with regulatory or legal professionals may be helpful for complex situations or when establishing compliance systems.

How long must I keep records of submitted reports?
It depends on product type. Drug and biologic manufacturers must retain records for 10 years. Dietary supplement companies must retain for 6 years.

Can I submit Form 3500A anonymously?
No. Mandatory reporters must identify themselves in Section G or F of the form. Anonymous reporting is only available for voluntary reports.

What is a “malfunction” that must be reported?
A malfunction is when a device fails to meet its performance specifications or otherwise perform as intended. It must be reported if it would likely cause or contribute to death or serious injury if it were to recur.

Are reports submitted on Form 3500A public?
Yes, with protections. Reports appear in public databases like FAERS and MAUDE, but patient and reporter identities are protected.

Do I need to report if the event was due to user error?
Yes. Device reports are required regardless of whether the event was caused by the device itself, user error, or other factors. The FDA evaluates all contributing factors.